【レポートの概要（一部）】
1. Report Overview
1.1 Global Next-Generation Antibody Therapies Market Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Antibodies: An Overview
2.2.1 Monoclonal versus Polyclonal Antibodies
2.2.2 A Brief History of Antibody Drug Development
2.2.3 The Antibody Manufacturing Process
2.2.4 Trends in Antibody Development
2.3 Defining Next-Generation Antibodies
2.3.1 Classification of Next-Generation Antibody Therapies
2.3.2 The Need for Next-Generation Technologies
2.4 Development Trends for Next-Generation Antibodies
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report
3. Next-Generation Antibody Therapies: World Market 2015-2025
3.1 The World Next-Generation Antibody Therapies Market in 2014
3.1.1 Next-Generation Antibody Therapies Market Segmentation, 2014
3.1.2 Leading Next-Generation Antibody Therapies Products
3.2 World Next-Generation Antibody Therapies Market: Sales Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2015-2025
4. Leading Regional Markets 2015-2025
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2015-2025
4.3 How Will Regional Market Shares Change to 2025?
4.4 US Next-Generation Antibody Therapies Market 2015-2025
4.5 EU5 Next-Generation Antibody Therapies Market 2015-2025
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2015-2025
4.7 Latin American Next-Generation Antibody Therapies Market 2015-2025
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2015-2025
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2015-2025
5.1 Antibody-Drug Conjugates: Market Overview, 2015
5.2 Leading ADCs in 2015
5.3 Antibody-Drug Conjugates: Market Forecast 2015-2025
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2015-2025
5.4.1 Competition for Leading Drugs Will Restrain Growth in 2015-2025
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics/Takeda)
5.5.1 Adcetris: Sales Forecast 2015-2025
5.5.2 Adcetris Meets Primary Endpoint in AETHERA Trial
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Kadcyla: Sales Forecast 2015-2025
5.6.2 Phase 3 Results for Kadcyla/Perjeta Combination Disappoint
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounts for Over 50% of the Pipeline
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Are Attracting High-Value Deals
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2025
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.2 Roche Attempts to Expand Kadcyla’s Breast Cancer Indication
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.13.1 Astellas Pharma: Partnered with Seattle Genetics for Phase 1 ADCs
5.13.2 Amgen’s AMG 595 (anti-EGFRv3) and AMG 172 (anti-CD27L)
5.13.3 Bayer’s Pipeline ADCs
5.13.3.1 Anetumab ravtansine (BAY 94-9343) (anti-mesothelin, Bayer)
5.13.3.2 C4.4a-ADC/BAY1129980 (anti-C4.4a, Bayer/Seattle Genetics)
5.13.3.3 FGFR2-ADC (anti-FGFR2, Bayer)
5.13.4 GSK2857916 (anti-BCMA, GSK/Seattle Genetics)
5.13.5 HuMax-TF-ADC (anti-TF, Genmab/Seattle Genetics)
5.13.6 ImmunoGen’s IMGN529 (anti-CD37), IMGN853 (anti-Folate receptor α) and IMGN289 (anti-EGFR)
5.13.7 LOP628 (anti-cKit, Novartis)
5.13.8 PF-06263507 (anti-5T4, Pfizer/Seattle Genetics)
5.13.9 Sanofi’s SAR408701 (anti-CEACAM5) and SAR566658 (anti-CA6)
5.13.10 SYD985 (trastuzumab duocarmycin; anti-HER2, Synthon)
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2015-2025
6.1 Engineered Antibodies: Market Overview, 2015
6.2 Leading Engineered Antibodies in 2015
6.3 Engineered Antibodies: Market Forecast 2015-2025
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2025
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo: Sales Forecast 2015-2025
6.6 Gazyva/Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva: Sales Forecast 2015-2025
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2015-2025
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
6.11.1 Ocaratuzumab (anti-CD20, Mentrik Biotech)
6.11.2 RG7116 (anti-HER3, Roche)
6.11.3 MGA271 (MacroGenics/Servier)
7. Bispecific Antibodies: Market Forecast and Pipeline 2015-2025
7.1 Bispecific Antibodies: Market Overview, 2015
7.2 Bispecific Antibodies: Market Forecast 2015-2025
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2015-2025
7.3.1 Manufacturing Bispecific Antibodies: Maintaining Stability and Purification
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2015-2025
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Blincyto: Sales Forecast 2015-2025
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2014-2024
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2025
7.8 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.8.1 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.8.2 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.8.3 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.8.4 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.8.5 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.8.6 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.9 Bispecific Antibodies: Phase 1 and Phase 1/2 Pipeline
7.9.1 COVA322 (anti-TNF and IL-17A, Johnson & Johnson)
7.9.2 IMCgp100 (anti-HLA-A2 and CD3, Immunocore)
7.9.3 Lymphomun (anti-CD20 and CD3, Trion Pharma/Fresenius Biotech)
7.9.4 MCLA-128 (anti-HER2 and HER3, Merus)
7.9.5 Rexomun (ertumaxomab) (anti-HER2 and CD3, Neopharm)
7.9.6 TF2 (anti-CEACAM5, Immunomedics)
7.9.7 AMG 211 (anti-CEA and CD3, Amgen/MedImmune)
7.9.8 BAY2010112 (MT112) (anti-PSMA and CD3, Bayer)
7.10 Bispecific Antibodies: Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2015-2025
8.1 Antibody Fragments and ALPs: Market Overview, 2015
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2025
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2015-2025
8.4 Kalbitor (ecallantide, Dyax)
8.4.1 Kalbitor: Sales Forecast 2015-2025
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2014-2024?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2015-2025
8.7 Antibody Fragments and ALPs: Phase 2 Pipeline
8.7.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7.1.1 Caplacizumab (anti-vWF)
8.7.1.2 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.7.1.3 Ozoralizumab (anti-TNFα)
8.7.1.4 ALX-0171 (anti-respiratory syncytial virus)
8.7.1.5 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.7.1.6 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.7.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.7.4 ESBA1008 (anti-VEGF, Novartis)
8.8 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9 Antibody Fragments and ALPs: Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2015-2025
9.1 Biosimilar Antibodies: Market Overview, 2015
9.2 Leading Biosimilar Antibodies in 2015
9.3 Biosimilar Antibodies: Market Forecast 2015-2025
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2015-2025
9.4.1.1 How Can Developers Ensure Uptake Among Physicians?
9.4.1.2 Automatic Substitution of Biosimilar Antibodies
9.4.1.3 Patent Expiries Will Hit Many Leading Antibodies in this Decade
9.4.1.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2015-2025
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths
10.1.1.1 Approved Products Indicate a Path to Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2015-2025
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr. Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, ArGEN-X, the Netherlands and Belgium
11.2.1 ArGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 ArGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for ArGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2025
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2025
12.2 The World Next-Generation Antibody Therapies Market in 2014
12.2.1 Current Leading Next-Generation Antibody Therapies Segments
12.2.2 Leading Novel Next-Generation Antibody Therapies
12.2.3 Leading Regional Markets
12.3 World Next-Generation Antibody Therapies Market Forecast 2015-2025
12.4 Next-Generation Antibody Therapies: Late-Stage Pipeline
12.5 The Future of the Next-Generation Antibody Therapies Market?
12.5.1 A Strong Phase 1 and Phase 2 Pipeline
12.5.2 Technology Platforms Will Continue to Attract Big Pharma Interest
12.5.3 Most Developers Continue to Target Cancer
12.5.4 Strategies for Growth in 2015-2025
13. Glossary
【レポート販売概要】
■ タイトル：次世代抗体療法の世界市場：抗体薬物複合体（ADC）、エンジニアード抗体、二重特異性抗体、抗体断片/ALP、バイオシミラー抗体■ 英文：Next-Generation Antibody Therapies Market Forecast 2015-2025 : Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052606
■ 調査対象地域：グローバル
- オキシ塩化チタンの世界市場Titanium Oxychloride (CAS 92344-13-3) Market Research Report 2014 presents comprehensive data on titanium oxychloride markets globally and regionally (Europe, Asia, North America etc.) The report includes titanium oxychloride description, covers its application areas and related patterns. It overviews titanium oxychloride market, names titanium oxychloride producers and indicates its suppliers. Be …
- 企業メタデータ管理の世界市場予測（～2022年）Increasing business data volume, centralized data management, operational excellence, regulations, and risk and compliance management are expected to propel the growth of the Enterprise Metadata Management marketThe global enterprise metadata management market size is expected to grow from USD 2.67 billion in 2017 to USD 7.85 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 24.1%. The d …
- 多変数トランスミッタの世界市場2019-2023About this market Flow measurements are essential for the safe and efficient running of a process plant. The market offers different types of flow technology measurement devices including multivariable transmitters. Multivariable pressure transmitters capture the static pressure: differential pressure. and temperature simultaneously. They also provide a consolidated output. thereby providing a fas …
- 眼科治療の世界市場2019-2023About this market The new drug approvals and strong drug pipeline will trigger the ophthalmology therapeutics market growth in the forthcoming years. Top players in the market are focusing on the development of disease-modifying drugs for treating the rising incidences of eye diseases. Furthermore, several market players are focusing on achieving new drug approvals and gene therapy approvals for t …
- 低血圧(Hypotension)：世界の治験レビュー（2015年上半期版）Hypotension Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Hypotension Global Clinical Trials Review, H1, 2015" provides data on the Hypotension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypotension. It includes an overview of the trial numbers and their recruitment status as per the site of …
- 世界のプロセス自動化及びインストルメンテーション市場The report, based on the extensive research study of the process automation market and instrumentation market, is aimed at identifying the entire market of process automation, specifically, the technology, hardware, software, services and the communication protocol.The market report also covers the field instruments used in the process industries. The report covers the overall market and sub-segme …
- 脱毛症(Alopecia)：世界の治験レビュー（2015年上半期版）Alopecia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2015" provides an overview of Alopecia clinical trials scenario. This report provides top line data relating to the clinical trials on Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe …
- 採掘装置レンタルの世界市場：装置タイプ別（露天採掘、地下採掘、粉砕、破砕・スクリーニング装置）、用途別（石炭採掘、金属採掘、鉱物採掘）、地域別予測Global Mining Equipment Rental Market to reach USD xx billion by 2025. Global Mining Equipment Rental Market valued approximately USD xx billion in 2016 is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2017-2025. One of the major drivers for this market is the rental advantages of mining equipment. Companies that function in a specific industry are busine …
- 世界のAmino Acids市場動向（2012-2016）TechNavio’s analysts forecast the Global Amino Acids market to grow at a CAGR of 25.5 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for amino acid-based dietary supplements. The Global Amino Acids market has also been witnessing an increase in mergers and acquisitions. However, stringent government regulatory norms for the app …
- 原発性硬化性胆管炎(Primary Sclerosing Cholangitis)の治療薬パイプライン動向（2015年上半期版）Primary Sclerosing Cholangitis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H1 2015’, provides an overview of the Primary Sclerosing Cholangitis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis, complete with comparative analysis at various stage …
- スターター肥料の世界市場予測（～2022年）The starter fertilizers market is projected to grow at a CAGR of 4.04% from 2016 to 2022, to reach a projected value of USD 8.33 Billion by 2022. Starter fertilizers have become prominent in the recent years, due to the increase in the area under forage & turf grasses, growth in awareness regarding the types of crops that can benefit from the use of starter fertilizers, and increase in research ac …
- Osteonecrosis：グローバル臨床試験レビューH2, 2013Osteonecrosis Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Osteonecrosis Global Clinical Trials Review, H2, 2013" provides data on the Osteonecrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteonecrosis. It includes an overview of the trial numbers and their recruitment status as per the …
- グローバルセイボリースナック 市場におけるM&A動向（2014年3月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global savory snacks market during March 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global savory snacks market throughout the month. Additionally, the report provides an overview of all th …
- オートメーション産業用モニターの世界市場2017-2021About Industrial Monitors Industrial monitors are widely used in a variety of industrial applications such as smart factories, mining operations, marine ports, food and beverage, oil rigs, and energy management. The ruggedness of industrial display differentiates these monitors from residential and commercial monitors. Industrial monitors are usually made of rugged materials to withstand the impac …
- 自動車産業における産業用ロボットの世界市場：多関節ロボット、直角座標ロボット、SCARAロボット、円筒座標ロボットAbout Industrial Robotics Industrial robotics can be defined as the use of robots in the manufacturing processes of industries such as food and beverage, electronics, and automotive. Industrial robots are programmed to control and automate manufacturing processes in industries. They are classified according to various technical parameters such as number of axes, degrees of freedom, working envelop …
